The estimated Net Worth of Robert Paul is at least $7.76 Milione dollars as of 9 August 2021. Mr. Paul owns over 22,950 units of Alector stock worth over $1,494,733 and over the last 5 years he sold ALEC stock worth over $3,955,198. In addition, he makes $2,307,860 as Chief Medical Officer at Alector.
Robert has made over 28 trades of the Alector stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 22,950 units of ALEC stock worth $245,336 on 9 August 2021.
The largest trade he's ever made was exercising 59,749 units of Alector stock on 6 July 2021 worth over $875,920. On average, Robert trades about 17,765 units every 22 days since 2019. As of 9 August 2021 he still owns at least 257,269 units of Alector stock.
You can see the complete history of Mr. Paul stock trades at the bottom of the page.
Robert Paul M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Paul joined Alector from Genentech, Inc., where he held various roles of increasing responsibility between 2009 and 2016, including as Assistant Group Medical Director and TA Head Neuroscience Early Clinical Development gRED from October 2015 to October 2016, as Senior Medical Director from October 2013 to September 2015, as Medical Director from September 2011 to October 2013, and as Associate Medical Director from January 2009 to September 2011. From May 2002 to December 2008, Dr. Paul served as a Neurologist at the University of Munich. Dr. Paul is a board certified neurologist in Germany. He received a M.D. and a Ph.D. from Ludwig-Maximilians Universität München.
As the Chief Medical Officer of Alector, the total compensation of Robert Paul at Alector is $2,307,860. There are 1 executives at Alector getting paid more, with Arnon Rosenthal having the highest compensation of $6,854,340.
Robert Paul is 52, he's been the Chief Medical Officer of Alector since 2016. There are 13 older and 6 younger executives at Alector. The oldest executive at Alector, Inc. is Louis Lavigne, 72, who is the Lead Independent Director.
Robert's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit... e Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: